Ariosa Diagnostics Inc. has notched another appellate win in the ongoing battle over patent rights to noninvasive prenatal testing, but this one could prove short-lived.
A few months after persuading the U.S. Court of Appeals for the Federal Circuit to invalidate competitor Sequenom Inc.’s patent on analyzing fetal DNA, Ariosa prevailed on the appellate court to give it a second chance in its inter partes review battle with Illumina Inc.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
